BioCentury
ARTICLE | Clinical News

Livatag: Completed Ph III ReLive enrollment

January 27, 2017 4:36 AM UTC

Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, FranceProduct: Livatag doxorubicin (Livatag doxorubicin Transdrug) (BA-003)Business: CancerMolecular target: DNADescription: Nanoparticle formulation of...

BCIQ Company Profiles

Onxeo S.A.